BOARD MEETING 4/2013

24 October 2013

MINUTES

INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

Title: Meeting of the Board of FIMM 4/2013 Time: Thursday, 24 October 2013, at 14.00—15.35 Place: FIMM Meeting Room D307a, Biomedicum Helsinki 2U, Tukholmankatu 8, Helsinki

Chair:

Vice Rector, Professor Kimmo Kontula, University of Helsinki

Members (Deputy Members):

Professor Kalle Saksela, Haartman Institute, Faculty of Medicine, University of Helsinki Professor Kimmo Porkka, Institute of Clinical Medicine, Faculty of Medicine, University of Helsinki; left in item 4.11 Professor Annamari Ranki, Institute of Clinical Medicine, Faculty of Medicine, University of Helsinki; arrived in item 4.11 Chief Research Officer, Professor Lasse Viinikka, HUS Senior Scientist, Head of Public Health Genomics Unit Anu Jalanko, THL Vice President, Professor, R&D Biotechnology Anu Kaukovirta-Norja, VTT CEO Saara Hassinen, Strategic Centre for Health and Well-being, SalWe Oy Director, Professor Eero Vuorio, Biocenter Finland Head of Laboratory Pekka Ellonen, FIMM Technology Centre

Experts:

Financial Manager Marja Medina, FIMM Head of Development Kimmo Pitkänen, FIMM

Presenter:

Director, Professor Olli Kallioniemi, FIMM

Secretary:

Administrative Manager Reetta Niemelä, FIMM

2(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

Meeting of the Board of FIMM 4/2013

1 Opening of the meeting and presence of a quorum

2 Approval of the agenda

3 Approval of the minutes of the previous meetings

4 Announcements

5 FIMM budget plan for 2014 and update of the Target Programme

6 Evaluation of suggested collaboration between FIMM/University of Helsinki and VTT in the field of metabolomics

7 The term of the current Board of FIMM

8 Other business

9 Date of the next meeting

10 Closing of the meeting

3(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

1 Opening of the meeting and presence of a quorum

Proposal: It was proposed that a quorum be present when the Chair of the meeting as well as at least half of the other members are present (FIMM Regulations 5 §).

Decision: It was recorded that a quorum was present.

2 Approval of the agenda

Proposal: It was proposed that the agenda be approved.

Decision: As proposed.

3 Approval of the minutes of the previous meetings

Proposal: 1. It was proposed that the minutes of the previous meeting held on 5 June 2013 is approved (Annex 1).

2. It was proposed that the minutes of the email meeting of 30 September 2013 is approved (Annex 2).

Decision: 1. As proposed.

2. As proposed.

4 Announcements

4.1 The FIMM 5-year Evaluation was carried out in May 2013. The Evaluation Report signed by Evaluation Committee Members is in Annex 3a. The public part of the Evaluation Report is available at http://www.fimm.fi/en/news/the_5-year_evaluation_report_of_fimm/. The Evalua- tion Report has been sent to FIMM stakeholders, including EMBL. The Director General of EMBL, Professor Iain Mattaj has introduced the Report and given a positive summary of FIMM progress at the EMBL Council Meeting in June 2013.

The signed statement of the Board of FIMM on those group leaders whose five-year term is ending in 2013—2014 is in Annex 3b.

4.2 The Board of the University of Helsinki selected Professor Jukka Kola the new Rector on 12 June 2013 and he started his five-year term on 1 August 2013 (http://www.helsinki.fi/administration/rector/index.html). The Board of the University decided on the Vice Rectors on 16 October 2013 as proposed by Rector Jukka Kola as follows: . Professor Keijo Hämäläinen, Dean of the Faculty of Science (responsible e.g. for educa- tion, research and innovation affairs, research infrastructures and collaboration with state research institutes) . Professor Anna Mauranen, Dean of the Faculty of Arts (responsible e.g. for international af- fairs and societal interaction) . Professor Pertti Panula, Vice Director of the Institute of Biomedicine and holder of a Swe- dish-speaking professorship (responsible e.g. for societal interaction, especially Nordic col- laboration and collaboration with HUS)

4(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

4.3 The first meeting with Rector Jukka Kola, the Directorship of the University of Helsinki and Di- rectors of the independent institutes of the University was held on 15 October 2013. The struc- tural development of the University was discussed and the Rector encouraged the independent institutes and faculties to be proactive and discuss joint initiatives in various activities.

4.4 Translational Medicine ESFRI infrastructure EATRIS has been established as a European Research Infrastructure Consortium (ERIC). Government's letter of 6 June 2013 regarding Finland's accession to the European Infrastructure for Translational Medicine (Valtioneu- voston kirjelmä eduskunnalle Suomen liittymisestä eurooppalaiseen translationaalisen lääketieteen tutkimusinfrastruktuurikonsortioon, EATRIS ERIC –konsortioon liittyminen) is in Annex 4.

EATRIS Constitutional Meeting will be arranged on 18—19 November 2013 in the Hague, the Netherlands, hosted by the Ministry of Education, Culture and Science. EATRIS is the first biomedical ESFRI to be approved as an ERIC.

4.5 In April 2013 the Academy of Finland FIRI expert group delivered to the Ministry of Education and Culture a recommendation for Finland to join the ERICs of EATRIS and BBMRI. The final BBMRI ERIC application was submitted to the European Commission in late May. Preparations for Finland to join BBMRI ERIC are underway. Olli Kallioniemi has been invited to and expert consultation of the Constitutional Law Committee of the Parliament of Finland on 22 Octo- ber 2013 (Asiantuntijakuuleminen eduskunnan sivistysvaliokunnassa; U 62/2013 vp Su- omen liittymisestä eurooppalaiseen biopankkeja ja biologisia aineistoja koskevaan tutki- musinfrastruktuurikonsortioon, BBMRI-ERIC -konsortioon liittyminen).

On 11 September 2013 Olli Kallioniemi participated in a panel discussion regarding biobanks in the Parliament of Finland.

4.6 Bioinformatics ESFRI infrastructure ELIXIR is in the process of being formally established as EMBL Special Project legal entity with UK, Sweden and EMBL having signed the Consortium Agreement (ECA). More countries including Finland are expected to join before the end of the year. Meanwhile the construction of the ELIXIR building has been completed at the Genome Campus in Hinxton, UK.

4.7 The Academy of Finland is updating the national roadmap for research infrastructures in 2013. The submission deadline of the stage 1 proposals was in February and stage 2 proposals in May 2013. The roadmap decision has been made by the Academy of Finland on 3 October 2013. Academy of Finland has also made a decision to have the roadmap approved by the Research and Innovation Council (Tutkimus- ja innovaationeuvosto, TIN). The next meeting of the Council is in mid-November.

4.8 The deadline of the research infrastructure call FIRI 2013 of the Academy of Finland was on 31 May 2013. According to the call text the Academy was prepared to fund research infrastruc- tures with 15 M€. Based on information of the Academy of Finland (http://www.aka.fi/en- GB/A/Academy-of-Finland/Media-services/Releases1/Academy-of-Finland-allocates-EUR-20- million-to-research-aimed-at-boosting-economic-growth/), the Board has decided to allocate 20 M€ to facilitate cutting-edge research and to launch two thematic research programmes. The appropriations are included in the Government’s third supplementary budget proposal for 2013. Of the funding, a total of 12 M€ will be used to support Centres of Excellence and research in- frastructures that are of key importance to Finland. FIRI-2013 decisions are expected by the end of November.

5(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

The FIRI funding is intended to support the construction of a new research infrastructure or the significant upgrading of an existing infrastructure. The funding is primarily allocated to invest- ment costs at the construction phase of infrastructures and to significant upgrading of existing infrastructures.

4.9 Biocenter Finland (BF) Technology Platform funding decision for 2014—2016 has been made at the University of Helsinki (decisions have not been made in all Biocenter Universities yet). FIMM has been granted 683 000 € for 2014 for the following Technology Platforms: Bioinfor- matics, Genome-Wide Methods, Metabolomics, Translational Technologies (Biobank and Drug discovery and chemical biology) and Viral Gene Transfer & Cell Therapy.

BF was searching for Director for the period of 1 January 2014—31 December 2016. The Rec- tors of the Biocenter Universities have appointed Professor Eero Vuorio the Director from 1 January 2014 to 31 December 2014, as he is available only for this one-year period. The Board of BF has set up a Search Committee to prepare a new call and to identify potential Direc- tor candidates. The new Director shall be appointed as of 1 January 2015.

4.10 The Ministry of Social Affairs and Health has sent a request for a statement to FIMM on the draft statute of the biobank consent document of the Finnish Government and the draft statute of the biobank communication of the Ministry of Social Affairs and Health (STM065:01/2012, 21.5.2013, Lausuntopyyntö luonnoksista valtioneuvoston asetukseksi bi- opankin suostumusasiakirjasta ja sosiaali- ja terveysministeriön asetukseksi biopankin tie- donannosta 5.7.2013 mennessä). FIMM statement in Annex 5a.

In addition, FIMM has given a statement on the draft statute on the charges of the regional ethics committee and the National Committee on Medical Research Ethics TUKIJA opinions (Lausunto luonnoksesta asetukseksi alueellisen eettisen toimikunnan ja valtakun- nallisen lääketieteellisen tutkimuseettisen toimikunnan lausunnoista perittävistä maksuis- ta). FIMM statement in Annex 5b.

4.11 The research project "Helsinki Urological Biobank HUB" filed a request to National Committee on Medical Research Ethics TUKIJA for an ethical opinion regarding registration of HUB as an official biobank. In its meeting on 1 October 2013, TUKIJA decided to ask for additional infor- mation. HUB is intended to be registered as a joint biobank of HUS and FIMM/University of Helsinki, and it will be merged with the HUS-erva regional biobank when operational. The pre- paratory work for registering the Finnish Hematology Registry and Biobank FHRB as an official biobank of the Finnish Hematology Association, the Finish Red Cross Blood Service and FIMM/University of Helsinki is currently under way.

4.12 Helsinki University Central Hospital and the University of Helsinki will establish a clinical bi- obank that will support the translational research done in the region, and network with national and international biobanks. The aim is to provide access, for ethically approved research pro- jects, to both previously collected sample collections (retrospective collections) and new sam- ples taken for diagnostic, treatment and monitoring purposes (prospective collections). The bi- obank will also support the regional research strategies of the hospital district and the Universi- ty. This Helsinki Academic Medical Center Biobank (HAMC Biobank) is owned by the Hospital District of Helsinki and Uusimaa (HUS), University of Helsinki, South Karelia Social and Health Care District (EKSOTE) and Kymenlaakso Social and Health Services (CAREA). After the offi- cial founding procedure is finalized during this year, HAMC Biobank aims to file ethical approv- al application forms to TUKIJA (National Committee on Medical Research Ethics) approximate- ly by the end of the year 2013. Simultaneously, separate ongoing or planned clinical sample collection projects in the region will be offered best of the chances to join as members of the HAMC Biobank.

4.13 Finnish network of biobanks (BBMRI.fi) has just launched a new web-site in September 2013 when the Biobank Law entered into force. Information is available in Finnish, Swedish and Eng- lish at http://biopankki.fi/.

6(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

4.14 THL (National Institute for Health and Welfare) has decided to establish a biobank, THL Bi- opankki.

4.15 FIMM joined the EU-LIFE network (European Life Sciences Institutes for Excellence) and signed the Memorandum of Understanding between the members of the network on 16 May 2013. The Founding Group of the EU-LIFE comprise nine institutes from Europe, including Cen- tre of Genomic Regulation (CRG, Barcelona, Spain; EMBL Partnership) and VIB (Zwijnaarde, Belgium), the current Chair and Vice Chair of the network.

The network is now willing to strengthen its collaboration and it has agreed that a Consortium Agreement will prepared. The Board of FIMM will be kept updated on the progress of the net- work. The next EU-LIFE Strategy Meeting will take place on 19—20 November 2013 in Brus- sels.

4.16 The Board of the University of Helsinki decided in April 2013 on the establishment of four doc- toral schools in the following fields: Humanities and social sciences, Natural sciences, Health sciences as well as Biological, environmental and food sciences. Dean of Research of the Fac- ulty of Medicine, Professor Hannu Sariola has been appointed the Director of the Health sci- ences school.

The schools will comprise doctoral programmes that are closely related in terms of their scien- tific foundation. Proposals for doctoral programmes were submitted in June 2013 and the Rec- tor decided that altogether 31 programmes will be established (Rector’s Decision 126/2013 of 20 June 2013 and annex is available at http://savotta.helsinki.fi/halvi/asianhallinta/dynasty/Rehtori.nsf?OpenDatabase). FIMM was in- volved in four proposals and they were all approved: HBGP-FIMM (Helsinki Biomedical Gradu- ate Program), Integrative Life Sciences, Brain and Mind as well as Drug Research Doctoral Program. In the Health sciences school there are altogether eight programmes and 49 new po- sitions for 2014—2017 as follows (some programmes have so far official names in Finnish on- ly): . HBGP-FIMM, 10 positions . Kliininen tohtoriohjelma, 9 positions . Väestön terveyden tohtoriohjelma (VTT), 7 positions . Suun terveystieteen tohtoriohjelma (FINDOS), 1 position . Drug Research Doctoral Program (DRDP), 5 positions . Integrative Life Sciences Doctoral Program (ILS), 10 positions . Brain and Mind Doctoral Program (B&M), 4 positions . Kliinisen ja translationaalisen eläinlääketieteen sekä eläinten terveyden ja hyvinvoinnin toh- toriohjelma (ANIWEL), 3 positions

At the moment there are altogether 54 doctoral students at FIMM, 26 of them in Academy of Finland doctoral programmes that in many cases served the basis for the new University of Helsinki doctoral programmes. These students will be transferred to the new doctoral pro- grammes in early 2014. The new arrangements of the programmes mean challenges for FIMM students: there are two pools of students (2013, 2014 starting DP years) competing for the fi- nancial resources at the same time. Recent information from the Rector's Office states that the funded positions can be 1—4 years in length, providing a mechanism for sharing the fully fund- ed, 4-year positions among two or more students. The reorganization will continue through the autumn and 2014, with 2014 being a major transition year.

4.17 In the FIMM 5-year Evaluation group leaders were in the focus, senior and postdoctoral re- searchers were not evaluated. However, they are key persons not only in research groups, but also in research infrastructures, institutional grand challenge projects, or in projects with the in- dustry. In addition, some senior researchers have roles and responsibilities in e.g. research training and science communication. Therefore, in the spirit of the EMBL, it was considered necessary to undertake a review of the senior researchers as well. The purpose of the review was to get an overview of the experienced researchers at FIMM their background, expertise and interests in the future. 7(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

In June 2013 there were altogether 47 senior researchers and postdoctoral researchers at FIMM. 20 of them participated in this review that was conducted for the first time (planned to be a continuous process). The review took place in September 2013. The general comments of the review are in Annex 6. In addition, each researcher received individual feedback.

4.18 New appointments at FIMM

FIMM Research Groups: . Om Prakash Dwivedi, Doctoral Student, 19.8.2013—23.8.2015, Group Groop . Mette Andersen, Postdoctoral Researcher, 1.9.2013—31.12.2013, Group Groop

Projects: . Vesa-Pekka Rahkama, Doctoral Student, 12.8.2013—15.8.2014, Tekes project/Biobank . Katja Välimäki, Senior Laboratory Technician, 19.8.2013—31.1.2016, IMI PREDECT . Outi Törnwall, Doctoral Student, 16.9.2013—31.12.2013, BBMRI-LPC

FIMM Technology Center: . Elina Huovari, Research Assistant, 7.6.2013—31.12.2013, Technology Center . Rigbe Weldatsadik, Research Assistant, 10.6.2013—9.8.2013, Internship related to Mas- ter’s studies/Technology Center . Kaisa Kettunen, Senior Researcher, substitute for Päivi Lahermo 17.9.2013—30.9.2014, Technology Center

FIMM-EMBL International PhD Training Intitiative: . Anna Cichonska, Doctoral Student, 19.8.2013—18.2.2015 . Balaguru Ravikumar, Doctoral Student, 19.8.2013—18.2.2015 . Sarang Talwelkar, Doctoral Student, 19.8.2013—18.2.2015

Trainees: . Barun Pradhan, Trainee, 4.6.2013—8.12.2013, Group Verschuren . Petri Jalovaara, Trainee, 2.9.2013—31.12.2013, Group Kainov . Heidi Alatalo, Trainee, 2.9.2013—28.2.2014, Administration

4.19 THL Research Professor and FIMM Senior Researcher Markus Perola has been appointed member of the Scientific Committee of IMI (Innovative Medicine Initiative).

4.20 New grants/projects at FIMM . IN-SENS (Deciphering Inter- and intracellular Signalling in Schizophrenia), FP7-PEOPLE- 2013-ITN (Initial Training Networks), Academy Research Fellow William Hennah.

4.21 Press releases . 18 June 2013, Tutkijat vauhdittavat terveyteen liittyvän geenitiedon maailmanlaajuista yh- teiskäyttöä http://savotta.helsinki.fi/halvi/tiedotus/lehti.nsf/e1e392ad852e72f5c225680000404fa8/7a91 0a349a879943c2257b8e003dc9a7?OpenDocument . 24 June 2013, Getting to grips with migraine - Researchers identify some of the biological roots of migraine from large-scale genome study/Tutkijat migreenin ytimessä - kan- sainvälinen tutkijaryhmä tunnisti toistakymmentä migreenigeeniä http://www.fimm.fi/en/news/getting_to_grips_with_migraine- _researchers_identify_some_of_the_biological_roots_of_migraine_from_large- scale_genome_study/ . 13 August 2013, Distinct brain disorders biologically linked - Disruption to the gene TOP3B increases susceptibility to schizophrenia and a learning disorder/Tutkijat löysivät suoma-

8(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

laiseen väestöön rikastuneen älyllisen kehityksen häiriöille ja skitsofrenialle altistavan geenimuutoksen http://savotta.helsinki.fi/halvi/tiedotus/lehti.nsf/e1e392ad852e72f5c225680000404fa8/e7bcc bef7af76ae6c2257bc6003461f5?OpenDocument . 22 August 2013, Avoin FinDis-tietokanta sisältää tiedon suomalaisen tautiperimän sairauk- sista http://savotta.helsinki.fi/halvi/tiedotus/lehti.nsf/e1e392ad852e72f5c225680000404fa8/4e69 3a570878e2c9c2257bcf00208669?OpenDocument

4.22 Olli Kallioniemi and Marja Pirttivaara (SITRA) were YLE Morning TV’s guests on 16 October. They discussed the possibilities of utilization of genomic data http://yle.fi/uutiset/oma_geenikartta_kertoo_tulevaisuuden_tautiriskeista/6884250?autoplay=tru e .

4.23 FIMM has prepared introduction videos in collaboration with the Franck Media production com- pany both in Finnish and in English. The main purpose of these videos is to present the drug sensitivity screening and NGS approaches to our on-site visitors in an easily understandable manner: . Lääkeherkkyystutkimus — mahdollisuuksia yksilöllistettyyn syöpähoitoon https://vimeo.com/67191892 . Perimän sekvensointi — mahdollisuuksia yksilöllistettyyn syöpähoitoon https://vimeo.com/67113202 . Drug sensitivity testing — new possibilities for personalised cancer treatment https://vimeo.com/74608507 . Genome sequencing — new possibilities for personalised cancer treatment https://vimeo.com/74608161

4.24 Events . FIMM, Helsinki Biomedical Graduate Program (HBGP) and National Graduate School of Clinical Investigation (CLIGS/VKTK) at the University of Helsinki organise the first sym- posium of the new Building Bridges series, Building Bridges Autumn 2013: Biobanking in Clinical and Translational Research. The Symposium will be held on 28—29 October, http://www.helisci.fi/vktk-kurssit/biobank/. . FIMM is involved in organizing the symposium: The 2nd Spotlight on Diagnostics — Evolving Applications, 20—22 November 2013 — Mauno Koivisto Centre, Turku, Finland. The symposium will focus on recent developments in diagnostics with a spotlight on the possibilities and challenges related to personalized medicine, point-of-care testing and the diagnostics of cancer and infectious and cardiovascular diseases. Further information at: http://www.turkusciencepark.com/tapahtumat/72/second-spotlight-diagnostics- evolving-applications/ . Nordic Council of Ministers, the Swedish Ministry of Education and Research, NordForsk and the Swedish Research Council will organise a conference on Nordic Cooperation on Research Infrastructures on 27—28 November 2013 in Stockholm, Sweden. Director of the Centre for Molecular Medicine Norway (NCMM), Professor Kjetil Taskén will repre- sent the Nordic EMBL Partnership. Further information at http://www.vr.se/NordicInfra2013. . Joint seminar with FIMM and the Neuroscience Center/University of Helsinki is post- poned from 29 November 2013 to 10 February 2014.

9(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

4.25 Visits at FIMM . Päijät-Häme area of the ERDF Southern Finland programme visited FIMM on 25 June 2013. . World Conference of Science Journalists was organized in Helsinki 24—28 June 2013. Olli Kallioniemi and Elisabeth Widén gave a presentation at the conference and some journal- ists visited FIMM. . Cancer Research UK, CRUK’s Executive Director, Strategic and Research Funding, Iain Foulkes ja Chief Scientist Nick Jones, 2 July 2013. . The Foreign Correspondents' Programme (FCP), a media training programme for young journalists arranged by the Ministry for Foreign Affairs of Finland (MFA), visited FIMM on 20 August 2013. . Senior Vice President and Director of Health Scienes Val Kratzman, Finpro, 21 August 2013. . ELIXIR Director Niklas Blomberg,3 October 2013. . President Stephen Friend from Sage Bionetworks will visit FIMM on 11—12 November 2013.

4.26 Prizes/awards

. The first Leena Peltonen Prize for Excellence in Human Genetics was awarded to Dr. Ce- cilia Lindgren in August 2013. The prize is awarded every second year and is funded by the Leena Peltonen Memorial Fund in the Paulo Foundation. It includes an award of 10 000 euros for a researcher who is in the early phase of his/her independent career. Olli Kallioniemi chaired the international nomination committee in 2013. Press release availa- ble at http://www.eurekalert.org/pub_releases/2013-08/uoh-tlp082713.php and http://savotta.helsinki.fi/halvi/tiedotus/lehti.nsf/e1e392ad852e72f5c225680000404fa8/a4e1 37f36ca6cd48c2257bd3002d264d?OpenDocument. . FiDiPro Professor Leif Groop has been named as the 2013 recipient of the Fernström Foundation Nordic Prize, with prize money of SEK 1 million, http://www.lunduniversity.lu.se/o.o.i.s?id=24890&news_item=6090.

10(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

5 FIMM budget plan for 2014 and update of the Target Programme (presenter: Kallioniemi)

The FIMM Target Programme prepared in 2012 is intended to cover the four year period 2013—2016. According to the guidelines of the Rector of the University of Helsinki the budg- et plan and human resources plan for 2014 need to be updated and only necessary updates to the text should be done.

In the draft FIMM Target Programme submitted to the Rector on 8 October 2013 the budget plan for 2014 is 12,4 M€ (Annex 7). However, e.g. funding for the graduate school positions as well as Academy of Finland Center of Excellence will still be completed in late 2013. The FIMM human resources plan for 2014 include 179 staff members. The Rector will give feed- back of the draft by 31 October 2013 and amendments will be done by 15 November 2013, if needed. The final budget plan will be presented to the Board in the next meeting on 4 De- cember 2013. The Board of the University of Helsinki will decide on the University’s Target Programme on 11 December 2013.

The text of the FIMM Target Programme has been updated regarding the forthcoming evalu- ation of the suggested collaboration between FIMM/University of Helsinki and VTT in the field of metabolomics. In addition, we have given some information on the budget plan concerning changes between years 2013 and 2014:

Part 1, Strategic framework, National special duties, international and academic special re- sponsibilities, coordination of networks, National agreements . Suggested collaboration in the field of metabolomics between FIMM/University of Helsinki and VTT will be evaluated by an international Evaluation Committee in October 2013. Based on the recommendations of the Evaluation Committee and the Board of FIMM the decision of the collaboration will be done by the Directorship of the University of Helsinki. If the collaboration will be implemented, it is expected to start in 2014. The possible reor- ganisation of activities include e.g. need for additional facilities in the Biomedicum Helsin- ki 2U building, reconstructuring these facilities, move of equipment, planning of human resources.

Part 2, Implementation of the Target Programme, Stable funding to maintain EMBL Partner- ship status . We have known for some years that year 2014 will be a challenging year for the budget of FIMM. The FIMM startup funds are ending, large ESFRI infrastructure projects are ending and new EU funds are not available until the new framework programme Hor- zon2020 starts in late 2014/early 2015. In order to prepare for this funding scenario, FIMM on purpose made a surplus in 2012 (975 k€) and small surpluses in 2011 and 2013 (total surplus >1 M€ currently). Our predictions are that the actual FIMM balance at the end of 2014 may be negative, in the range of 200-300 k€. . In basic funding we have estimated the institute´s overheads to be 1 M€ (0,5 M€ included in Internal UH income). We have also included 100 k€ additional support from HUS, however negotiations with the City of Helsinki are still underway. According to the RETO - meeting (30 May 2013), the University of Helsinki will decide about the additional strate- gic support of 150 k€ (Rector´s total strategic funding expected to be 300 k€). . Regarding external funding, decreasing funding level was already expected in early 2013. The funding from the Academy of Finland will decrease because a big Biomedinfra- project (ESFRI, about 2 M€/year) comes to an end in 2013. In addition four EU-projects have ended in 2013 (ERDF-project as well as FP7 -projects: EU-OPENSCREEN, EN- GAGE and Gen2Phen).Due to EU's budget cycles and introduction of the new Hori- zon2020 programme, no new EU funding is expected until late 2014 or early 2015.

11(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

Part 3, Resources, Facilities plan . In 2013 FIMM has completed the first phase of reconstruction work in Biomedicum Hel- sinki 2U building (wings 3D and 3F) to optimise the use of space. If the FIMM/University of Helsinki-VTT collaboration will be implemented there is a need for additional laboratory space (ca. 260 m2) and office space (ca 100 m2) available in Biomedicum Helsinki 2U building (wings 1F and 1G). These facilities will also need some reconstruction work as the possible collaboration include move of equipment and 17 persons.

The whole 23-page draft Target Programme was available at the Board meeting on 24 Octo- ber 2013

Proposal: It was suggested that the Board confirms the update of the budget for 2014 as presented in Annex 7 and the texts of the Target Programme mentioned above.

Decision: As proposed.

12(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

6 Evaluation of suggested collaboration between FIMM/University of Helsinki and VTT in the field of metabolomics (presenter: Kallioniemi)

The Directorship of VTT and the University of Helsinki discussed the possible collaboration between FIMM/University of Helsinki and VTT in the field of metabolomics in May 2013. Based on these discussions and later discussions of the Board of FIMM as well as repre- sentatives of FIMM/University and VTT it has been agreed that the possible reorganization of metabolomics to the University of Helsinki will be evaluated by an international Evaluation Committee. Rector Jukka Kola gave the Board of FIMM mandate to appoint the Evaluation Committee comprising of experts suggested by FIMM and VTT. The Board of FIMM ap- proved the composition of the Committee at its email meeting in September as follows (An- nex 2): . Professor Kai Simons, Max-Planck-Institute of Molecular Cell Biology and Genetics, Ger- many (Chair of SAB and the Evaluation Committee) . Professor Ari Helenius, ETH Zürich, Switzerland . Professor Andrej Shevchenko, Max-Planck-Institute of Molecular Cell Biology and Genet- ics, Germany . Professor Markus Wenk, National University of Singapore, Singapore . Professor Lothar Willmitzer, Max Planck Institute of Molecular Plant Physiology Golm, Germany

The Evaluation Committee’s site visit will take place on 30—31 October 2013. The evaluation material is comprised on the following documents; all documents were available for the Board Members as well.

Evaluation Material: 1. FIMM-UH-VTT Metabolomics Evaluation 30—31 October 2013, programme for the site visit in Annex 8a 2. FIMM/University of Helsinki and VTT Views on Collaboration, Annex 8b 3. Research Professor Matej Oresic's View on FIMM-VTT Collaboration, how the possible transfer of metabolomics/QBIX Group (Quantitative Biology and Bioinformatics Group) from VTT to the University of Helsinki would be carried out, Annex 8c 4. Matej Oresic's Dossier (Annex 8d) and five publications (publications in the electronic material only)

Other background documents 5. FIMM 5-year Evaluation Report 2013 6. FIMM Annual Report 2012 7. Background information on the new VTT organization 2014— (reform underway) 8. VTT presentation slides 2013 9. VTT review 2012

The final decision on the possible transfer of the activities from VTT to the FIMM/University of Helsinki will be done at the University level based on the recommendations of the Evaluation Committee and statement of the Board of FIMM.

As stated in item 5 of this Agenda and summary document from FIMM/University of Helsinki, FIMM will have a tight budget year in 2014 due to the fact that major externally funded re- search and infrastructure projects come to an end, and FIMM will not be able to contribute much to the planned collaboration and reorganisation. We would expect that Matej Oresic’s group is largely supporting itself with EU grants at the moment. Questions to be discussed between VTT and FIMM/University of Helsinki include how VTT will support the possible re- organization/transfer of activities and how this support will continue if the reorganization will be implemented.

13(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

Matej Oresic gave a presentation to FIMM staff on 23 October 2013. The title of his presenta- tion was: Metabolomics/lipidomics research and technologies at VTT and the planned collab- oration with FIMM. The Board was invited to the seminar as well. Matej Oresic is also availa- ble for the next Board Meeting on 4 December 2013.

Proposal: 1. It was suggested that the Board completes the Evaluation Committee with one additional member, Professor Thomas Moritz from the Swedish Metabolomics Center, Swedish Univer- sity of Agricultural Sciences, Umeå, Sweden.

2. It was suggested that the Board establishes of a working group to prepare the statement of the Board for the Directorship of the University of Helsinki and VTT.

Decision: 1. As proposed.

2. As proposed. The Board nominated Chair of the Board, Professor Kimmo Kontula and the following Members of the Board to the working group: Professors Anna-Elina Lehesjoki, Risto Renkonen, Lasse Viinikka and Anu Kaukovirta-Norja. Professors Lehesjoki and Renkonen had confirmed their availability as they were not present at the Board Meeting.

7 The term of the current Board of FIMM

Rector of the University of Helsinki appointed the members and deputy members of the cur- rent Board of FIMM in June 2010 for a four-year period from 1 July 2010 to 31 March 2014 (Annex 9).

According to the Regulations of FIMM (3 §, http://www.fimm.fi/midcom-serveattachmentguid- 1dfd84f3f7dd56ed84f11df93555ff7dd071aab1aab/fimm_regulations_2010.pdf) The Board of the Institute shall comprise a maximum of nine members and a chairperson. The members each have a personal deputy. The term of the Board is four years. The University of Helsinki appoints three members to the Board, and HUS, THL and VTT each name one member. The University of Helsinki invites a representative from an industry that benefits from the Insti- tute’s research to serve on the Board. One member shall be appointed from among the Insti- tute’s staff. In addition, the University of Helsinki may invite a member to represent the Bio- center Finland network. The University of Helsinki appoints the Chair of the Board.

The Board discussed the composition of the Board as of 1 April 2014. The Chair of the Board, Professor Kimmo Kontula will discuss with Rector Jukka Kola the chairpersonship of the Board as of 1 April 2014.

8 Other business

There was no other business.

9 Date of the next meeting

It was suggested that the 1/2014 Board Meeting will be held in late February or March 2014. Suggestion of dates will be sent to the Board Members.

14(15) INSTITUTE FOR MOLECULAR MEDICINE FINLAND FIMM Nordic EMBL Partnership for Molecular Medicine

9 Closing of the meeting

The Chair closed the meeting at 15.35

Helsinki 4 December 2013

Kimmo Kontula Professor, Vice Rector Chair, Board of FIMM

Olli Kallioniemi Professor Director of FIMM Presenter

Reetta Niemelä Administrative Manager of FIMM Secretary

15(15)